The ESSENCE trial tested injectable semaglutide in adults with a form of fatty liver disease and moderate to advanced scarring [1]. Our guide to GLP-1 drugs and fatty liver disease explains who the findings apply to. This trial measured changes in liver tissue at week 72.
What the trial found at 72 weeks
The interim analysis covered a cohort of 800 participants, the first to be randomized. It included 534 assigned to semaglutide and 266 assigned to placebo. Steatohepatitis resolved without worsening fibrosis in 62.9% and 34.3%, respectively [1]. Fibrosis improved without worsening steatohepatitis in 36.8% and 22.4%. Both improvements occurred in 32.7% and 16.1%.
Average weight loss was 10.5% with semaglutide and 2.0% with placebo. Gastrointestinal side effects were more common in the semaglutide group. The trial was designed to run for 240 weeks. The interim results tell us how liver tissue changed, while longer follow-up evaluates clinical outcomes.
What dose did the trial study?
The trial targeted a 2.4 mg weekly injection after a 16-week escalation [1] [2]. The 72-week period includes dose escalation. It does not represent 72 weeks at 2.4 mg. The study did not test compounded semaglutide.
The FDA granted accelerated approval to injectable Wegovy for adults with noncirrhotic MASH and stage F2 or F3 fibrosis [2]. The MASH label recommends 2.4 mg weekly for maintenance. It allows 1.7 mg if the higher dose is not tolerated. Continued approval may depend on confirmation of clinical benefit.
What to check when estimating costs
Your cost depends on coverage and the prescription. If you have a confirmed monthly price, the GLP-1 cost calculator can estimate what you would pay over time. Ask whether that price applies when the dose changes.